JP2022507686A5 - - Google Patents
Info
- Publication number
- JP2022507686A5 JP2022507686A5 JP2021527084A JP2021527084A JP2022507686A5 JP 2022507686 A5 JP2022507686 A5 JP 2022507686A5 JP 2021527084 A JP2021527084 A JP 2021527084A JP 2021527084 A JP2021527084 A JP 2021527084A JP 2022507686 A5 JP2022507686 A5 JP 2022507686A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- use according
- cell
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770437P | 2018-11-21 | 2018-11-21 | |
| US62/770,437 | 2018-11-21 | ||
| PCT/US2019/062494 WO2020106898A1 (en) | 2018-11-21 | 2019-11-20 | Pharmaceutical methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507686A JP2022507686A (ja) | 2022-01-18 |
| JP2022507686A5 true JP2022507686A5 (https=) | 2022-12-12 |
Family
ID=70774631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527084A Pending JP2022507686A (ja) | 2018-11-21 | 2019-11-20 | 薬学的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230149377A1 (https=) |
| EP (1) | EP3883561A4 (https=) |
| JP (1) | JP2022507686A (https=) |
| KR (1) | KR20210099022A (https=) |
| AU (1) | AU2019384802A1 (https=) |
| CA (1) | CA3120366A1 (https=) |
| IL (1) | IL283273A (https=) |
| MX (1) | MX2021005936A (https=) |
| SG (1) | SG11202105221XA (https=) |
| TW (1) | TW202033189A (https=) |
| WO (1) | WO2020106898A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024137821A1 (en) * | 2022-12-21 | 2024-06-27 | Elevar Therapeutics, Inc. | Effect of rivoceranib on cytochrome p450 enzyme substrates |
| WO2025261988A1 (fr) * | 2024-06-17 | 2025-12-26 | Assistance Publique Hopitaux De Paris | Utilisation de nintédanib pour le traitement de la maladie de castleman |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| AU2013204181A1 (en) * | 2006-11-06 | 2013-05-16 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| CN101675930B (zh) * | 2008-09-16 | 2012-04-25 | 江苏恒瑞医药股份有限公司 | 用于治疗增生性疾病的药物组合物 |
| EP3141245A1 (en) * | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| CN106038566B (zh) * | 2016-06-10 | 2018-11-27 | 江阴市人民医院 | 一种用于胃癌治疗的药物组合物及其应用 |
| CN107669685A (zh) * | 2016-08-02 | 2018-02-09 | 江苏恒瑞医药股份有限公司 | 阿帕替尼与替加氟和紫杉类药物联合用于制备治疗胃癌的药物中的用途 |
-
2019
- 2019-11-20 CA CA3120366A patent/CA3120366A1/en active Pending
- 2019-11-20 JP JP2021527084A patent/JP2022507686A/ja active Pending
- 2019-11-20 WO PCT/US2019/062494 patent/WO2020106898A1/en not_active Ceased
- 2019-11-20 MX MX2021005936A patent/MX2021005936A/es unknown
- 2019-11-20 KR KR1020217018983A patent/KR20210099022A/ko not_active Abandoned
- 2019-11-20 SG SG11202105221XA patent/SG11202105221XA/en unknown
- 2019-11-20 TW TW108142221A patent/TW202033189A/zh unknown
- 2019-11-20 EP EP19887000.8A patent/EP3883561A4/en not_active Withdrawn
- 2019-11-20 US US17/295,848 patent/US20230149377A1/en not_active Abandoned
- 2019-11-20 AU AU2019384802A patent/AU2019384802A1/en not_active Abandoned
-
2021
- 2021-05-19 IL IL283273A patent/IL283273A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507686A5 (https=) | ||
| WO2020024820A1 (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| CN107635547B (zh) | 用于治疗和预防肿瘤的甲苯哒唑多形体 | |
| CN106883193B (zh) | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 | |
| JP2019503384A5 (https=) | ||
| JP2023531049A (ja) | Ｓｏｓ１阻害剤及びｋｒａｓ ｇ１２ｃ阻害剤を含む抗がん剤併用療法 | |
| WO2020024826A1 (en) | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop | |
| IL272697B2 (en) | A polymorphic form of TG02 | |
| CN108135900A (zh) | 包含瓦尼替尼及抗癌剂之组合疗法 | |
| JP2021525768A5 (https=) | ||
| JP2019509354A5 (https=) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| RU2015105786A (ru) | Комбинированная терапия ингибиторами igf1r и pi3k | |
| CN104582708A (zh) | 用于治疗小细胞肺癌的苯并二氮*类 | |
| JP2021502415A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| CN103153292A (zh) | 联合抗癌疗法 | |
| RU2014142057A (ru) | Комплексная терапия | |
| JP2024522304A5 (https=) | ||
| JP2017528460A5 (https=) | ||
| JP2014513144A (ja) | 進行性又は転移性固形悪性腫瘍を含む固形悪性腫瘍の治療方法 | |
| WO2018214925A1 (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| CN114177299A (zh) | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 | |
| JP2014144979A (ja) | 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤 | |
| JP5858989B2 (ja) | 組合せ | |
| US20150094321A1 (en) | Combination |